| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
1,220,000,000 |
| Market
Cap: |
14.30(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$8.77 - $13.53 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 979 |
| Guru Rank Value : 0 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Viatris is a global healthcare company. Co.'s portfolio comprises more than 1,400 approved molecules across a range of key therapeutic areas. Co. has four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. Key products sold by the Developed Markets segment include Lyrica®, Lipitor®, Creon®, Influvac®, Wixela™ Inhub™, and the EpiPen® Auto-Injector. Key products within the Greater China segment include Lipitor®, Norvasc®, and Viagra®. Key products within the JANZ segment include AMITIZA®, Lipacreon®, Lyrica®, Norvasc®, and Effexor®. Among Co.'s products sold in the Emerging Markets segment are Lipitor®, Lyrica®, Norvasc®, Celebrex®, and anti-retrovirals.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
323,885 |
346,822 |
346,822 |
376,566 |
| Total Sell Value |
$3,944,486 |
$4,172,428 |
$4,172,428 |
$4,507,109 |
| Total People Sold |
5 |
5 |
5 |
7 |
| Total Sell Transactions |
6 |
9 |
9 |
14 |
| End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Goettler Michael |
Chief Executive Officer |
• • – |
2021-02-22 |
4 |
D |
$15.50 |
$23,591 |
D/D |
(1,522) |
6,081 |
|
- |
|
| Goettler Michael |
Chief Executive Officer |
• • – |
2021-02-22 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,499 |
7,603 |
|
- |
|
| Kilts James M |
Director |
– • – |
2020-12-16 |
4 |
B |
$17.66 |
$489,693 |
D/D |
27,736 |
64,905 |
2.39 |
-25% |
|
| Kilts James M |
Director |
– • – |
2020-11-16 |
4/A |
A |
$0.00 |
$0 |
D/D |
35,764 |
36,044 |
|
- |
|
| Pfizer Inc |
10% Owner |
– – • |
2020-11-16 |
4 |
D |
$0.00 |
$0 |
D/D |
(689,874,047) |
0 |
|
- |
|
| Korman Harry |
Director |
– • – |
2020-11-16 |
4 |
A |
$0.00 |
$0 |
D/D |
26,515 |
26,701 |
|
- |
|
| Lyons Dillon Joellen |
Director |
– • – |
2020-11-16 |
4 |
A |
$0.00 |
$0 |
D/D |
15,609 |
15,609 |
|
- |
|
| Higgins Melina E |
Director |
– • – |
2020-11-16 |
4 |
A |
$0.00 |
$0 |
I/I |
74,000 |
74,000 |
|
- |
|
| Higgins Melina E |
Director |
– • – |
2020-11-16 |
4 |
A |
$0.00 |
$0 |
D/D |
39,131 |
39,131 |
|
- |
|
| Parrish Mark W |
Director |
– • – |
2020-11-16 |
4 |
A |
$0.00 |
$0 |
D/D |
58,295 |
58,313 |
|
- |
|
| Coury Robert J |
Executive Chairman |
• • – |
2020-11-16 |
4 |
A |
$0.00 |
$0 |
D/D |
1,383,587 |
1,383,587 |
|
- |
|
| Campbell Paul |
See Remarks |
• – – |
2020-11-16 |
4 |
A |
$0.00 |
$0 |
I/I |
826 |
508 |
|
- |
|
| Campbell Paul |
See Remarks |
• – – |
2020-11-16 |
4 |
A |
$0.00 |
$0 |
D/D |
30,336 |
30,420 |
|
- |
|
| Van Der Meer Mohr Pauline |
Director |
– • – |
2020-11-16 |
4 |
A |
$0.00 |
$0 |
D/D |
6,265 |
6,265 |
|
- |
|
| Malik Rajiv |
President |
• • – |
2020-11-16 |
4 |
A |
$0.00 |
$0 |
I/I |
88,365 |
88,365 |
|
- |
|
| Malik Rajiv |
President |
• • – |
2020-11-16 |
4 |
A |
$0.00 |
$0 |
D/D |
459,699 |
460,319 |
|
- |
|
| Kilts James M |
Director |
– • – |
2020-11-16 |
4 |
A |
$0.00 |
$0 |
D/D |
36,889 |
37,169 |
|
- |
|
| Dimick Neil F |
Director |
– • – |
2020-11-16 |
4 |
A |
$0.00 |
$0 |
D/D |
51,263 |
51,263 |
|
- |
|
| Mark Richard A |
Director |
– • – |
2020-11-16 |
4 |
A |
$0.00 |
$0 |
D/D |
9,228 |
9,228 |
|
- |
|
| Pfizer Inc |
10% Owner |
– – • |
2020-11-13 |
4 |
A |
$0.00 |
$0 |
D/D |
689,873,947 |
689,874,047 |
|
- |
|
| Pfizer Inc |
10% Owner |
– – • |
2020-08-06 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
100 |
|
- |
|
221 Records found
|
|
Page 9 of 9 |
|
|
0.10 (0.85%) 
